Literature DB >> 18175781

Nephropathy in males and females with Fabry disease: cross-sectional description of patients before treatment with enzyme replacement therapy.

Alberto Ortiz1, João P Oliveira, Steven Waldek, David G Warnock, Bruno Cianciaruso, Christoph Wanner.   

Abstract

BACKGROUND: Fabry disease, an X-linked genetic disorder with deficient alpha-galactosidase A activity, is characterized by kidney disease and kidney failure. The spectrum of kidney disease has not been well defined, especially in female patients.
METHODS: We did a cross-sectional retrospective analysis of natural history of glomerular filtration rate (estimated- eGFR), albuminuria and proteinuria in 1262 adult patients (585 males, 677 females) from the Fabry Registry.
RESULTS: Twenty-eight percent of males (age 20-79 years) and 13% of females (age 20-82 years) had chronic kidney disease (CKD) with eGFR < 60 ml/min/1.73 m(2). Overt proteinuria (>300 mg/24 h) was demonstrated in 43 and 26% of males and females with CKD stage 1, respectively, and the proportions were higher with more severe kidney involvement. However, 11% of males and 28% of females with eGFR < 60 ml/min/1.73 m(2) had proteinuria <300 mg/ 24 h. Of eGFR >/= 60 ml/min/1.73 m(2) patients without overt proteinuria (n = 93), 55% of the males and 35% of the females had albuminuria >30 mg/24 h. Systemic blood pressure was >/=130/80 mmHg in 48% and 67% of patients with eGFR >/= and <60 ml/min/1.73 m(2), respectively, with no significant differences between males and females. Proteinuria values were significantly correlated with systolic blood pressure in both sexes.
CONCLUSIONS: Kidney involvement in Fabry disease is more prevalent and heterogeneous than previously reported. Proteinuria is an early complication, but may not be overt in patients with advanced kidney disease. This analysis, which includes more females than males, confirms that a significant proportion of females suffer moderate to severe kidney involvement in Fabry disease.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18175781     DOI: 10.1093/ndt/gfm848

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  62 in total

1.  Increased arterial stiffness is associated with high cardiovascular mortality in male Fabry patients.

Authors:  Kathleen Nicholls
Journal:  J Inherit Metab Dis       Date:  2011-12-14       Impact factor: 4.982

Review 2.  [Females with Fabry's disease - an interdisciplinary diagnostic and therapeutic challenge].

Authors:  Frank Weidemann; Markus Niemann; Claudia Sommer; Meinrad Beer; Frank Breunig; Christoph Wanner
Journal:  Med Klin (Munich)       Date:  2010-09-28

3.  The Prevalence and Clinical Features of Fabry Disease in Hemodialysis Patients: Russian Nationwide Fabry Dialysis Screening Program.

Authors:  Sergey Moiseev; Victor Fomin; Kirill Savostyanov; Alexander Pushkov; Alexey Moiseev; Andrey Svistunov; Leyla Namazova-Baranova
Journal:  Nephron       Date:  2019-01-24       Impact factor: 2.847

4.  Heat shock protein 90 and NFkB levels in serum and urine in patients with chronic glomerulonephritis.

Authors:  Natalia Chebotareva; Anatoliy Vinogradov; Alla Gindis; Ekaterina Tao; Sergey Moiseev
Journal:  Cell Stress Chaperones       Date:  2020-04-02       Impact factor: 3.667

Review 5.  Assessment of renal pathology and dysfunction in children with Fabry disease.

Authors:  Uma Ramaswami; Behzad Najafian; Arrigo Schieppati; Michael Mauer; Daniel G Bichet
Journal:  Clin J Am Soc Nephrol       Date:  2010-01-07       Impact factor: 8.237

6.  A case of female Fabry disease revealed by renal biopsy.

Authors:  Sae Aratani; Hiroyuki Yamakawa; Shinya Suzuki; Tomoyuki Otsuka; Yukinao Sakai; Akira Shimizu; Shuichi Tsuruoka
Journal:  CEN Case Rep       Date:  2019-09-21

7.  Scoring system for renal pathology in Fabry disease: report of the International Study Group of Fabry Nephropathy (ISGFN).

Authors:  Agnes B Fogo; Leif Bostad; Einar Svarstad; William J Cook; Solange Moll; Federic Barbey; Laurette Geldenhuys; Michael West; Dusan Ferluga; Bojan Vujkovac; Alexander J Howie; Aine Burns; Roy Reeve; Stephen Waldek; Laure-Hélène Noël; Jean-Pierre Grünfeld; Carmen Valbuena; João Paulo Oliveira; Justus Müller; Frank Breunig; Xiao Zhang; David G Warnock
Journal:  Nephrol Dial Transplant       Date:  2009-10-15       Impact factor: 5.992

8.  Fabry disease: progression of nephropathy, and prevalence of cardiac and cerebrovascular events before enzyme replacement therapy.

Authors:  Raphael Schiffmann; David G Warnock; Maryam Banikazemi; Jan Bultas; Gabor E Linthorst; Seymour Packman; Sven Asger Sorensen; William R Wilcox; Robert J Desnick
Journal:  Nephrol Dial Transplant       Date:  2009-02-13       Impact factor: 5.992

Review 9.  Fabry disease: recent advances in pathology, diagnosis, treatment and monitoring.

Authors:  Björn Hoffmann
Journal:  Orphanet J Rare Dis       Date:  2009-10-11       Impact factor: 4.123

10.  Safety and efficacy of enzyme replacement therapy in the nephropathy of Fabry disease.

Authors:  Fernando C Fervenza; Roser Torra; David G Warnock
Journal:  Biologics       Date:  2008-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.